Feed / LQDA

Liquidia Corporation

LQDA

Healthcare · 68.59 -3.5% today

Isolated · not yet confirmedMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Liquidia Corporation's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.

Revenue YoY+1031.2%2025-12-31
Operating margin-32.5%+834.2 pts YoY
Company-3.5% todayVolume comparison unavailable
Market group0 of 1 activePulmonary Hypertension Drugs · unavailable
Disclosed network0 of 6 confirmingNo filing-linked name is confirming now
What would change this read
  • YUTREPIA revenue increased with higher sales volume, making commercial demand the clearest current operating driver.
  • Operating cash flow improved sharply, but management identified $12.8 million of unfavorable working-capital changes.

Invalidation: The isolated read changes if LQDA's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind LQDA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ICUIICU Medical, Inc.supplierMay 11, 2026

To administer Treprostinil Injection through subcutaneous injection, patients currently must use the CADD-MS 3 infusion pump manufactured by ICU Medical.

UTHRUnited Therapeutics CorporationcompetitorMay 11, 2026

Our Treprostinil Injection product to treat PAH faces competition primarily from the continued use of the branded Remodulin sold by United Therapeutics as well as additional generic treprostinil products offered by Teva, Par Pharmaceutical, Dr.

Depended on by

UTHRUnited Therapeutics CorporationcompetitorJul 30, 2025

In addition, in May 2025 Liquidia received FDA approval of Yutrepia for PAH and PH-ILD, which now competes with our treprostinil-based products.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

LQDA is currently a Leader in the organic co-movement group Pulmonary Hypertension Drugs. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for LQDA; it is not active in the latest market snapshot.